Supply_NNP We_PRP have_VBP some_DT 15,000_CD people_NNS at_IN 30_CD manufacturing_NN sites_NNS in_IN 20_CD countries_NNS ,_, dedicated_VBN to_TO ensuring_VBG that_IN we_PRP can_MD deliver_VB a_DT secure_JJ ,_, high_JJ quality_NN ,_, cost-effective_JJ supply_NN of_IN our_PRP$ product_NN range_NN worldwide_NN ._.
With_IN a_DT few_JJ temporary_JJ exceptions_NNS ,_, major_JJ products_NNS and_CC line_NN extensions_NNS were_VBD successfully_RB supported_VBN with_IN supplies_NNS available_JJ to_TO meet_VB market_NN demand_NN ._.
These_DT included_VBD the_DT continued_VBN global_JJ roll-out_NN of_IN Crestor_NNP ,_, the_DT European_JJ launches_NNS of_IN Exanta_NNP and_CC the_DT completion_NN in_IN all_DT major_JJ markets_NNS of_IN the_DT launch_NN of_IN the_DT Zoladex_NNP Safesystem_NNP ,_, designed_VBN to_TO protect_VB against_IN needlestick_NN injuries_NNS when_WRB handling_VBG the_DT injectable_JJ Zoladex_NNP therapy_NN ._.
Managing_VBG costs_NNS is_VBZ an_DT ongoing_JJ priority_NN ._.
2004_CD saw_VBD the_DT continued_VBN implementation_NN across_IN our_PRP$ global_JJ network_NN of_IN our_PRP$ new_JJ supply_NN system_NN ,_, which_WDT is_VBZ delivering_VBG manufacturing_VBG efficiency_NN benefits_NNS such_JJ as_IN shortened_JJ lead_NN times_NNS and_CC improved_VBN customer_NN service_NN levels_NNS ._.
We_PRP continue_VBP to_TO invest_VB for_IN the_DT future_NN ._.
Our_PRP$ expenditure_NN on_IN supply_NN and_CC manufacturing_NN facilities_NNS totalled_VBD $_$ 352_CD million_CD in_IN 2004_CD and_CC new_JJ facilities_NNS authorised_VBN included_VBD formulation_NN capacity_NN for_IN Symbicort_NNP in_IN France_NNP ,_, for_IN Pulmicort_NNP in_IN the_DT US_NNP and_CC for_IN Nexium_NNP in_IN Sweden_NNP ._.
We_PRP also_RB continuously_RB review_VB our_PRP$ existing_VBG manufacturing_VBG assets_NNS to_TO make_VB sure_JJ they_PRP are_VBP being_VBG used_VBN most_RBS effectively_RB ,_, whilst_IN preserving_VBG the_DT flexibility_NN we_PRP need_VBP to_TO respond_VB to_TO fluctuations_NNS in_IN demand_NN ._.
During_IN 2004_CD ,_, we_PRP sold_VBD our_PRP$ facility_NN in_IN Karlskoga_NNP ,_, Sweden_NNP ._.
